Gland Pharma
GLAND.NSApprovedFounded in 1978, Gland Pharma has grown into one of the world's largest injectable-focused companies, renowned for its high-quality manufacturing and extensive product portfolio. The company is majority-owned by Shanghai Fosun Pharmaceutical and has a significant presence in the US market through its subsidiary in Princeton, New Jersey. Its strategic focus includes expanding its CDMO services, developing complex injectable products, and leveraging its expertise in biologics and sterile injectables to drive growth in key therapeutic areas.
GLAND.NS · Stock Price
Historical price data
AI Company Overview
Founded in 1978, Gland Pharma has grown into one of the world's largest injectable-focused companies, renowned for its high-quality manufacturing and extensive product portfolio. The company is majority-owned by Shanghai Fosun Pharmaceutical and has a significant presence in the US market through its subsidiary in Princeton, New Jersey. Its strategic focus includes expanding its CDMO services, developing complex injectable products, and leveraging its expertise in biologics and sterile injectables to drive growth in key therapeutic areas.
Technology Platform
Specializes in advanced sterile injectable manufacturing technologies for complex generics, including capabilities in biologics, peptides, hormones, and oncology drugs, operating as a CDMO.
FDA Approved Drugs
155Opportunities
Risk Factors
Competitive Landscape
Competes with global injectable specialists like Pfizer (Hospira), Fresenius Kabi, Hikma, and Indian peers like Sun Pharma and Dr. Reddy's. Differentiation is achieved through scale, a strong regulatory track record, and specialized expertise in complex peptides, hormones, and oncology injectables.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile